Table 1 Patient demographics and HAE treatment characteristics

Age, mean (range)

47.5 (28–72)

Gender, female, n (%)

9 (64.3)

Race, n (%)

 White

13 (92.9)

 Black

1 (7.1)

Time since HAE diagnosis, years, mean (range)

31 (6–61)

Employment status, n (%)

 Full time

8 (57.1)

 Part time

2 (14.3)

 Retired

2 (14.3)

 Full-time parent

1 (7.1)

 Unemployed due to HAE

1 (7.1)

Comorbidities (self-reported), n (%)

 None

6 (40.0)

 Allergic rhinitis/conjunctivitis or seasonal allergies

5 (33.3)

 Hypertension

4 (26.7)

 Anxiety

3 (20.0)

 Depression

2 (13.3)

 Asthma

2 (13.3)

 GERD

1 (6.7)

 Anemia

1 (6.7)

 Hypothyroidism

1 (6.7)

 Positive ANA nucleolar 1:640

1 (6.7)

Prior HAE prophylaxis

 Plasma-derived C1INH(IV)

9 (64.3)

 Androgens

2^a (14.3)

 No long-term prophylaxis

2 (14.3)

 Unknown

1 (7.1)

Current on-demand treatment, n (%)

 Icatibant only

9 (64.3)

 Icatibant and plasma-derived C1INH(IV)

2 (14.3)

 Icatibant and recombinant C1INH(IV)

1 (7.1)

 Plasma-derived C1INH(IV) only

1 (7.1)

 Recombinant C1INH(IV) only

1 (7.1)